A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1

AIDS

Volumn 16, Issue 2, 2002, Pages 227-233

  Armbruster, Christine ^a,c   Stiegler, Gabriela M ^a   Vcelar, Brigitta A ^a   Jäger, Walter ^a   Michael, Nelson L ^b   Vetter, Norbert ^a   Katinger, Hermann W D ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c NONE   (Austria)

Author keywords

HIV therapy; HIV 1; Human monoclonal antibodies; Pharmacokinetics; Safety

Indexed keywords

CD4 ANTIGEN; HUMAN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; BLOOD CELL COUNT; BLOOD CHEMISTRY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INTRAVENOUS ADMINISTRATION; LYMPHOCYTE COUNT; MALE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTIBODIES, MONOCLONAL; CD4 LYMPHOCYTE COUNT; CONSUMER PRODUCT SAFETY; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; RNA, VIRAL;

EID: 0037169214     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200201250-00012     Document Type: Article

References (25)

1. Longitudinal HIV-1 RNA levels in a cohort of homosexual men
2. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
3. HIV-1 rebound after antiretroviral therapy
4. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
5. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
6. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate
7. Generation of human monoclonal antibodies against HIV-1 proteins; Electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization
8. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1
9. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection
10. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
11. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
12. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
13. Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies
14. A phase I/II study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120
15. PASSHIV-1 treatment of patients with HIV-1 infection. A preliminary report of a phase I trial of hyperimmune porcine immunoglobulin to HIV-1
16. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120
17. Monoclonal antibodies given as passive treatment of HIV-infected individuals
18. Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1
19. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: The Scan Study
20. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or CXCR4 coreceptor
21. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a clinical population. Royal Free Centre for HIV Medicine
22. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns
23. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1 b12
24. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules
25. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1